(BBC) Virtus LifeSci Biotech - Ratings and Ratios
Biotech, Clinical Trials, Phase 1, Phase 2, Phase 3
Dividends
| Dividend Yield | 1.63% |
| Yield on Cost 5y | 1.29% |
| Yield CAGR 5y | 182.63% |
| Payout Consistency | 32.5% |
| Payout Ratio | - |
| Risk via 5d forecast | |
|---|---|
| Volatility | 36.5% |
| Value at Risk 5%th | 61.3% |
| Relative Tail Risk | 2.07% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.34 |
| Alpha | 42.60 |
| CAGR/Max DD | 0.26 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.464 |
| Beta | 1.084 |
| Beta Downside | 1.009 |
| Drawdowns 3y | |
|---|---|
| Max DD | 54.45% |
| Mean DD | 18.86% |
| Median DD | 16.60% |
Description: BBC Virtus LifeSci Biotech January 02, 2026
The Virtus LifeSci Biotech Clinical Trials ETF (NYSE ARCA: BBC) is designed to allocate at least 80 % of its capital to the constituents of its underlying index, which tracks U.S.-listed biotechnology firms whose lead drug candidates are in Phase 1-3 clinical trials and have not yet secured FDA marketing approval.
Key sector drivers that can materially affect BBC’s performance include (1) the rate of FDA approvals, which historically averages about 15 % of Phase 3 candidates per year; (2) R&D intensity, with the biotech industry spending roughly 20-25 % of revenue on research-a metric that correlates with pipeline robustness; and (3) macro-level funding conditions, as venture capital inflows to early-stage biotech have risen 12 % YoY in 2024, supporting valuation growth for trial-stage companies. These factors together shape the fund’s risk-return profile, but the exact impact on BBC will depend on the mix of trial phases and therapeutic areas represented in the index.
For a deeper quantitative breakdown, you might explore the fund’s metrics on ValueRay.
What is the price of BBC shares?
Over the past week, the price has changed by +7.60%, over one month by +0.43%, over three months by +37.61% and over the past year by +82.08%.
Is BBC a buy, sell or hold?
What are the forecasts/targets for the BBC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 48.2 | 21.9% |
BBC Fundamental Data Overview January 07, 2026
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 33.7m USD (33.7m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 33.7m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 33.7m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 9.91% (E(33.7m)/V(33.7m) * Re(9.91%) + (debt-free company))
Discount Rate = 9.91% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for BBC ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle